GlassScriptPhysician profile
Adam T Stys
NPI 1083656821
$7,344.97
in general payments reported to CMS, 2019-2025
36 companies · $975 in 2025
The $975 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,606 · 2020: $816 · 2021: $1,021 · 2022: $513 · 2023: $904 · 2024: $509 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,134.05 | 2019-2025 | Cardiomems, Diamondback Peripheral, Amplatzer Amulet |
| Medtronic, INC. | $1,030.08 | 2021-2025 | Corevalve Evolut R, In.Pact Admiral, Micra |
| Abiomed | $903.41 | 2020-2025 | Impella |
| Acist Medical Systems, INC. | $546.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $473.21 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $401.08 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $297.69 | 2020-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $240.20 | 2019-2025 | Farxiga, Wainua |
| Medtronic Vascular, INC. | $155.55 | 2019-2020 | |
| Edwards Lifesciences Corporation | $143.73 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $134.50 | 2023-2025 | General - Therapies, Wolverine Coronary Cutting Balloon, Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $132.94 | 2019-2025 | Evkeeza |
| Chiesi USA, INC. | $64.02 | 2019-2021 | |
| Amarin Pharma, INC. | $63.30 | 2020-2022 | |
| Daiichi Sankyo INC. | $57.95 | 2023-2024 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.93 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $54.17 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $53.73 | 2025 | Amvuttra |
| Cardiovascular Systems INC. | $41.84 | 2019-2021 | |
| Asahi Intecc USA, INC. | $38.54 | 2020-2022 | |
| Reflow Medical INC | $35.07 | 2025 | |
| Shockwave Medical, INC | $32.39 | 2021-2022 | |
| Amgen INC. | $28.04 | 2020-2025 | Repatha |
| Philips North America LLC | $27.78 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Portola Pharmaceuticals, LLC | $24.76 | 2019-2020 | |
| Lundbeck LLC | $23.77 | 2020-2021 | |
| United Therapeutics Corporation | $22.39 | 2019 | |
| Becton, Dickinson and Company | $21.34 | 2025 | True Flow |
| Bard Peripheral Vascular, INC. | $19.86 | 2024 | True Flow |
| Vifor Pharma, INC. | $16.89 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.21 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $15.55 | 2025 | Verquvo |
| Astellas Pharma US INC | $13.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Stys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.